ArticleCureus2025
Contribution of Cytology to the Diagnosis of Chediak-Higashi Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized by partial oculocutaneous albinism, recurrent infections, and giant intracytoplasmic granules in leukocytes. Early diagnosis is critical to prevent the onset of severe complications, particularly the accelerated phase. We conducted a descriptive case series in the Hematology Laboratory of Ibn Rochd University Hospital Center, Casablanca. All patients diagnosed with CHS based on cytological analysis were included. Complete blood counts were performed using the SYSMEX® XN-1500 analyzer (Sysmex Corporation, Kobe, Japan), and peripheral blood and bone marrow smears were stained with May-Grünwald Giemsa. Five patients (three girls and two boys) were identified, with a mean age of four years and 11 months. Parental consanguinity was present in all cases. Clinical findings included oculocutaneous albinism (n=4), splenomegaly (n=4), lymphadenopathy (n=3), and recurrent bacterial infections (n=4). Cytological analysis revealed pathognomonic giant granules within granulocytes in all patients. All patients developed hemophagocytic lymphohistiocytosis and succumbed to disease-related complications. In resource-limited settings, cytological evaluation remains a crucial tool for diagnosing CHS when genetic testing is unavailable. Early identification of suggestive clinical features, combined with cytological findings, can facilitate prompt diagnosis and timely initiation of appropriate management, including hematopoietic stem cell transplantation, the only curative treatment available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.